2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regression
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatients
2016
The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment
Obeng-Gyasi S, Tolnitch L, Greenup R, Shelley Hwang E. The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. Annals Of Surgical Oncology 2016, 23: 3412-3417. PMID: 27411550, PMCID: PMC5994757, DOI: 10.1245/s10434-016-5311-3.Peer-Reviewed Original Research
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomyEvaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?
Bahl M, Baker J, Greenup R, Ghate S. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? Annals Of Surgical Oncology 2015, 22: 435-441. PMID: 26249144, DOI: 10.1245/s10434-015-4792-9.Peer-Reviewed Original ResearchConceptsPathologic nipple dischargeMagnetic resonance imagingNipple dischargeNegative predictive valuePositive predictive valuePredictive valueDiagnostic valueNegative magnetic resonance imagingSpecificity of MRIBreast magnetic resonance imagingEvaluation of patientsValuable additional diagnostic toolRadiology Breast Imaging ReportingBI-RADS 1Data System 4Detection of malignancyAdditional diagnostic toolBreast Imaging ReportingSonographic workupDuct explorationRetrospective reviewSurgical excisionRadiographic findingsDuctal carcinomaSymptomatic population
2013
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Annals Of Surgical Oncology 2013, 20: 3254-3258. PMID: 23975317, DOI: 10.1245/s10434-013-3205-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBRCA mutation prevalenceRace/ethnicityBRCA mutationsGenetic counselingBreast cancerMutation prevalenceGenetic mutationsAfrican AmericansHereditary cancer clinicBRCA mutation statusBRCA genetic mutationPersonalized genetic counselingConclusionsThe prevalenceNCCN guidelinesPrimary outcomeRetrospective reviewTNBC subtypesResultsA totalBRCA2 mutationsCancer clinicMutation statusDemographic dataPrevalenceEthnicity/race
2012
Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs
Camp M, Greenup R, Taghian A, Coopey S, Specht M, Gadd M, Hughes K, Smith B. Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs. Annals Of Surgical Oncology 2012, 20: 836-841. PMID: 23010735, DOI: 10.1245/s10434-012-2664-0.Peer-Reviewed Original ResearchMeSH KeywordsAxillaBreast NeoplasmsCombined Modality TherapyCost-Benefit AnalysisFemaleFollow-Up StudiesHumansLymph Node ExcisionLymphatic MetastasisMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicPrognosisRetrospective StudiesSentinel Lymph Node BiopsySurvival RateConceptsAxillary lymph node dissectionCompletion axillary lymph node dissectionPerioperative surgical managementOvernight admissionPerioperative costsZ0011 criteriaSurgical managementBreast cancerSentinel lymph node-positive breast cancerLymph node-positive breast cancerNode-positive breast cancerACOSOG Z0011 criteriaACOSOG Z0011 trialOvernight hospital admissionLymph node dissectionRetrospective chart reviewInvasive breast cancerBreast conservation therapyInpatient hospital daysPositive breast cancerExcellent regional controlPositive SLNZ0011 trialEligible patientsNode dissection